{"id":297,"date":"2025-06-23T10:00:00","date_gmt":"2025-06-23T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=297"},"modified":"2025-09-11T09:42:17","modified_gmt":"2025-09-11T09:42:17","slug":"china-bd-2025-harbour-biomed-and-otsuka-enters-a-670-million-usd-license-on-bcmaxcd3-bispecific-t-cell-engager-hbm7020","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/297.html","title":{"rendered":"[China BD 2025] Harbour BioMed and Otsuka enters a 670 million USD License on BCMAxCD3 bispecific T-cell engager HBM7020"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2025-06-22 (June 22, 2025)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Name: HBM7020<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor (Seller): Harbour BioMed (China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): Otsuka Pharmaceutical\uff08Japan\uff09<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: bispecific antibody, T cell-engager (TCE),  <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target: BCMAxCD3\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential Indication: autoimmune diseases, cancer<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Stage until the deal: Phase I in China<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Otsuka is granted an exclusive license to develop, manufacture, and commercialize HBM7020, a BCMAxCD3 bispecific T-cell engager globally, excluding Greater China (Mainland China, Hong Kong, Macau and Taiwan).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Payment Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Harbour BioMed will receive<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upfront and near-term payments US$47 million, .<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Development and commercial milestonesup to US$623 million.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tiered royalties on future net sales.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.harbourbiomed.com\/news\/243.html\">Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers-HBM Holdings<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Note:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chinese Name of \u201cHarbour BioMed\u201c, \u201c\u548c\u94c2\u533b\u836f\u201d\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-06-22 (June 22, 2025) Asset Name: HBM7020 Licensor (Seller): Harbour BioMed (China) Licensee (Buyer): &hellip; <a title=\"[China BD 2025] Harbour BioMed and Otsuka enters a 670 million USD License on BCMAxCD3 bispecific T-cell engager HBM7020\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/297.html\"><span class=\"screen-reader-text\">[China BD 2025] Harbour BioMed and Otsuka enters a 670 million USD License on BCMAxCD3 bispecific T-cell engager HBM7020<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-297","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=297"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/297\/revisions"}],"predecessor-version":[{"id":298,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/297\/revisions\/298"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}